Reneo’s PhIIb rare disease trial failure forces layoffs, cost cuts — stock plummets
Reneo Pharmaceuticals’ stock plunged by 82% as it revealed plans to slash 70% of its workforce after its only drug candidate disappointed in a registrational …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
